Suchergebnisse - "Sessa, C"

PubPharm (422)

31

An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib

enthalten in: Targeted oncology | 2016

von Mateo, J. | Moreno, V. | Gupta, A. | +15

32

An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib

enthalten in: Targeted oncology | 2016

von Mateo, J. | Moreno, V. | Gupta, A. | +15

33

An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib

enthalten in: Targeted oncology | 2016

von Mateo, J. | Moreno, V. | Gupta, A. | +15

34

An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib

enthalten in: Targeted oncology | 2016

von Mateo, J. | Moreno, V. | Gupta, A. | +15

35

ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer : diagnosis, treatment and follow-up

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2016

von Colombo, N. | Creutzberg, C. | Amant, F. | +51

CommentIn: Ann Oncol. 2016 Feb;27(2):212-3. - PMID 26658892

36

ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up

enthalten in: Annals of oncology | 2016

von Marth, C. | Colombo, N. | Bosse, T. | +8

37

Genetic susceptibility to cutaneous melanoma in southern Switzerland: role of CDKN2A ,MC1R and MITF

enthalten in: The British journal of dermatology | 2016

von Mangas, C. | Potrony, M. | Mainetti, C. | +12

38

The ESMO guideline strategy : an identity statement and reflections on improvement

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2015

von Pentheroudakis, G. | Cardoso, F. | Arnold, D. | +32

39

Integrative population pharmacokinetic and pharmacodynamic dose finding approach of the new camptothecin compound namitecan (ST1968)

enthalten in: British journal of clinical pharmacology | 2015

von Joerger, M. | Hess, D. | Delmonte, A. | +7

40

Phase-I dose finding and pharmacokinetic study of the novel hydrophilic camptothecin ST-1968 (namitecan) in patients with solid tumors

enthalten in: Investigational new drugs | 2015

von Joerger, M. | Hess, D. | Delmonte, A. | +4